New: Introducing the Finviz Futures Map

Aquestive Therapeutics, Inc.

Contributing Author

Recent Articles by Aquestive Therapeutics, Inc.

Aug-26	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences AQST GlobeNewswire
Aug-14	Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock AQST GlobeNewswire
Aug-14	Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm (epinephrine) Sublingual Film AQST GlobeNewswire
Aug-11	Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update AQST GlobeNewswire
Aug-04	Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET AQST GlobeNewswire
Jul-22	Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer AQST GlobeNewswire
Jul-15	Aquestive Therapeutics Provides International Expansion Update for Anaphylm (epinephrine) Sublingual Film AQST GlobeNewswire
Jul-07	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism AQST GlobeNewswire
Jun-25	Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit AQST GlobeNewswire
Jun-16	Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm for the Treatment of Severe Allergic Reactions AQST GlobeNewswire
May-12	Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update AQST GlobeNewswire
May-05	Aquestive Therapeutics to Participate in Citizens Life Sciences Conference AQST GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.